Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva’s More Convenient Copaxone Puts Payors In A Bind

Feb 24 2014

Related Content

Copaxone Reduces Its Dosing Schedule, But Can It Shrink The Competition?

Jan 31 2014

Biogen Idec Undercuts <em>Gilenya</em> With $55,000 Yearly Price For <em>Tecfidera</em>

Apr 01 2013

Copaxone’s Tombstone? 2014 Could Be Year Generic Launches, Momenta Says

Feb 17 2014

Teva’s Final Copaxone Firewall Is Complexity Of ANDA Review After Court Tosses Patent

Jul 26 2013

Related Companies

Teva Pharmaceutical Industries Ltd.

Viatris Inc.

Novartis AG

Novartis AG

Momenta Pharmaceuticals, Inc.

Natco Pharma Limited

Biogen, Inc.

Acorda Therapeutics, Inc.

Merck KGaA

Merck KGaA

Bayer AG

Additional Topics

United States Business Strategies Pricing Strategies Leadership Reimbursement BioPharmaceutical

More from Business Strategy

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window